

Title: Consensus Guideline for the Management of Peritoneal Metastases in Patients with Neuroendocrine Neoplasms

Running Title: Peritoneal metastases in neuroendocrine neoplasms

Authors: PSM Neuroendocrine Neoplasm Writing Group, PSM Consortium Group, Kiran Turaga

Correspondence:

Kiran K. Turaga, MD, MPH, FACS
Division Chief of Surgical Oncology
Yale School of Medicine
FMB130J, 330 Cedar St,
New Haven, CT, 06511, USA
kiran.turaga@yale.edu

Consensus Guideline for the Management of Peritoneal Metastases in Patients with Neuroendocrine Neoplasms

ABSTRACT (word count: 248)

Background

Neuroendocrine neoplasms (NEN) with peritoneal metastases (PM) represent a complex clinical challenge due to low incidence and heterogeneous phenotypes. This manuscript describes the results of a national consensus aimed at addressing clinical management of patients with NEN-PMs.

Methods

An update of the 2018 Chicago consensus guidelines was conducted using a modified Delphi technique, encompassing two rounds of voting. The levels of agreement for various pathway blocks were rigorously assessed. Key systemic therapy concepts were summarized by content experts. Supporting evidence was evaluated via a rapid literature review.

Results

Overall, the level of evidence for the management of PM in this disease was universally low. In total, 107 participants responded in the first round, with 88/107 (82%) participating in the second round. Strong consensus (> 90%) was achieved in 5/7 (71%) and 7/7 (100%) blocks in rounds I and II respectively. A multidisciplinary approach including psychosocial and wellness assessments received a strong positive recommendation. Management of NENs with PMs was organized according to disease grade and symptom profiles. In grade 1 and 2 well-differentiated NENs, cytoreductive surgery (CRS) received strong support (>95%) following the management of functional syndromes (if present). For grade 3 well-differentiated NENs, systemic therapy is the primary recommendation, with surgical resection considered in select cases. Poorly differentiated NENs (i.e. neuroendocrine carcinomas) are predominantly treated with chemotherapy.

Conclusion

Given limited evidence, the consensus-driven clinical pathway offers vital clinical guidance for the management on NENs with PM. The need for high-quality evidence remains critical to the field.

INTRODUCTION

Neuroendocrine neoplasms (NENs) are a diverse group of malignancies that arise from neuroendocrine cells throughout the body. As per the 2022 World Health Organization (WHO) classification scheme, well-differentiated NENs are defined as neuroendocrine tumors (NETs), whereas poorly differentiated NENs are distinguished as neuroendocrine carcinomas (NECs).¹ The incidence and prevalence of NENs, including small intestine NENs, have increased nearly three-fold in the last three decades, and they are now recognized as the second most prevalent gastrointestinal neoplasm and tenth most prevalent neoplasm overall.^{2,3} The incidence of peritoneal metastasis (PM) in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) can range from 19% to 60%, most of which originate from primary midgut tumors.⁴⁻⁶

Prognosis in patients with NENs and PM (NEN-PM) varies broadly with primary tumor location, concurrent hepatic involvement, tumor grade, and patient age, with 5-year survival rates ranging from 7% to 67%.⁶ As two of the more common distant sites of disease in NENs, PM and hepatic metastases often occur concurrently.¹ While common, the presence of PMs does not necessarily portend a poorer survival rate compared to other distant metastatic sites.⁶

In 2018, the Chicago Consensus Working Group provided multidisciplinary recommendations for the management of NEN-PMs.^{7,8} Evidence studying this disease subset remains largely retrospective and scarce. Hence, there are currently no established standard of care pathways for the management of NENs with PMs.

Herein, we present the results of a national consensus on the clinical management of patients with NENs with PM, updated in line with recent evidence synthesized through a rapid systematic review evaluating optimal management strategies for GEP-NENs with PMs.

METHODS

This initiative was part of a national multidisciplinary consortium group process aimed at streamlining guidelines for the care of patients with peritoneal surface malignancies (PSM). The consensus and rapid review methodology has been described in detail in a separate manuscript (Submitted).⁹ Major components are summarized below.

Consensus Group Structure

In brief, the Neuroendocrine Working Group consisting of seven neuroendocrine experts who volunteered to lead the section (PK, TH, JS, DM, AG, JK, EB). Two core group members (DS, LB) coordinated the effort. A team of six surgical residents and surgical oncology fellows conducted the rapid reviews.

Modified Delphi Process

A modified Delphi method with two rounds of voting was employed to gather feedback regarding the clinical management pathway following preliminary synthesis of major updates since the last guideline iteration.¹⁰ Experts rated their agreement levels on a five-point Likert scale via a Qualtrics questionnaire. A 75% consensus threshold was set, with blocks below 90% agreement undergoing further review. Simultaneously, a summary table outlining first-line systemic therapies was generated.

Rapid Review of the Literature

A MEDLINE search via PubMed between January 2000 and August 2023 addressed the key question: What is the optimal management strategy for abdominal NENs with peritoneal metastases? A search strategy was developed and reviewed by a medical librarian specialist, and the review protocol was pre-registered in PROSPERO ([CRD42023465271](https://doi.org/10.1111/CRD4.2023.465271)).¹¹ The Covidence platform facilitated title & abstract screening, full-text review, data extraction, and quality assessment using the Newcastle Ottawa Scale for non-randomized studies.¹²⁻¹⁴ The review was conducted in alignment with recommendations from the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.^{15,16}

External Perspectives

Multiple patient advocates within the Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS) reviewed the treatment pathway offered insights regarding clinical trial enrollment, research outcomes, and available resources for patients with NEN-PMs. Additionally, members of the Peritoneal Surface Oncology Group International

(PSOGI) Executive Council were invited to appraise the second version of the pathway. Their comments were consolidated to evaluate alignment with global practices regarding the management of NEN-PMs.

RESULTS

In all, 107 invited experts voted in the first Delphi round, of which 82% (n = 88) responded in the second round. Of survey responders, 72 (67%) were surgical oncologists, 18 (17%) medical oncologists, 10 (9%) pathologists, 3 (3%) radiologists, and 4 (3%) experts in other domains. Given the low quality of existing evidence in the literature, recommendations were based primarily on expert opinion. This pathway was divided into seven main blocks (Figure 1; Supplementary Figure S1) and agreement % is summarized in Tables 1-2.

A rapid review evaluating optimal management strategies in GEP-NENs with PMs revealed 2023 abstracts as detailed in the PRISMA flow diagram (Figure 2). Twenty-three full texts were reviewed, and 9 studies were included for data extraction and quality assessment and cited in relevant sections of the document (Table 3; Supplementary Table S1-S2).^{4,5,17-23}

Summary of Major Updates

Building upon the 2018 Chicago Consensus Guideline, the current approach involves a more stringent consensus and review methodology while engaging a larger spectrum of experts and patient advocates.^{7,8} The updated guidelines highlight a comprehensive preoperative evaluation including psychosocial support, nutrition, fertility considerations, and linkage with patient advocacy groups. Steering away from the prior classification based primarily on liver involvement, the updated pathway draws attention to NEN-PMs based on disease grade, symptomatology, and tumor burden. The management of grade 1 and 2 well-differentiated NETs is segregated based on symptom profiles, addressing carcinoid syndrome, as well as obstruction in the setting of carcinoid-associated mesenteric fibrosis or carcinomatosis. For well-differentiated grade 3 GEP-NETs, a relatively new World Health Organization (WHO) class with limited treatment data, the primary approach leans towards systemic therapy.¹ Surgery can be considered in patients

with disease amenable to near-complete cytoreduction. Meanwhile, medical management with cytotoxic chemotherapy is recommended for NECs due to their aggressive nature and low likelihood of clinical benefit from surgical intervention.

Block-Based Recommendations

Block 1: Preoperative considerations

Agreement: Round 1 - 97%; Round 2 - 97%

Preoperative evaluation includes a thorough examination of history and physical findings, diagnostic workup, and a multidisciplinary tumor board discussion.²⁴⁻²⁶ This includes a detailed assessment of functional symptoms, such as carcinoid syndrome and carcinoid heart disease. Additionally, we emphasize the early involvement for patient support groups, social work, genetic counseling, fertility specialists, psychosocial support, and programs dedicated to exercise and nutritional wellness for preoperative optimization.^{27,28}

Molecular profiling of NENs, while not routinely performed for diagnostic purposes, may be helpful in distinguishing cases of G3 NETs from NECs.^{1,29-31} The role of germline testing is evolving but remains controversial, as it has traditionally only been offered to patients with a high clinical suspicion for inherited endocrine syndromes, such as multiple endocrine neoplasia, tuberous sclerosis, neurofibromatosis, or von Hippel Lindau syndrome. These germline alterations make up a very small percentage of GEP-NENs and occur more frequently in pancreatic NENs.³²⁻³⁵

The recommended imaging modalities are multiphasic CT or MRI of the abdomen and pelvis and somatostatin-receptor (SSTR)-based PET imaging, which may be either SSTR-PET/CT or SSTR-PET/MRI using ⁶⁸Ga-DOTATATE or ⁶⁴Cu-DOTATATE.³⁶ In the presence of liver metastases, MRI imaging is considered the modality of choice due to high signal intensities observed on T2-weighted imaging.³⁷ Overall, PMs remain difficult to characterize radiographically due to small tumor volume, multifocality, and tissue density, but may be more apparent on DOTATATE PET scans.³⁸ Assessment of metastatic burden remains critical in the preoperative evaluation as this influences overall surgical candidacy.

Block 2: Stratification by grade

Agreement: Round 1 - 92%; Round 2 - 96%

Grading of GEP-NENs is classified by proliferation rate using the Ki-67 index and the mitotic count. Well-differentiated disease is stratified into three grades (Grade 1, 2, and 3): grade 1 NETs have a mitotic rate < 2 mitoses/ 2 mm^2 and a Ki-67 index $< 3\%$, grade 2 NETs have a mitotic rate 2-20 and/or Ki-67 index of 3-20%, and grade 3 NETs have a mitotic rate >20 or Ki-67 index $>20\%$. NECs are molecularly and histologically distinct from well-differentiated NETs and are highly aggressive, demonstrating a Ki-67 index $> 20\%$; however, usually above 50%.¹

In our consensus-based pathway, peritoneal involvement in neuroendocrine neoplasms (NENs) is stratified based on histopathological grading: Grade 1/2 NET, Grade 3 NET, and NEC. This categorization aligns with the WHO system and is pivotal in clinical decision-making and prognostic estimations.¹

Block 3: Grade 3 GEP-NETs and NECs

Agreement: Round 1- 87%; Round 2 - 96%

Well-differentiated grade 3 GEP-NETs (NET-G3) is a relatively new category in the 2017 and 2019 WHO classifications.^{1,39} The sequence of surgical and systemic therapy offered in NET-G3 with PMs is more nuanced as many prior surgical trials and studies had mixed NEC and NET-G3.^{40,41} Furthermore, many surgical studies focus on non-metastatic NET-G3 or do not subgroup by PM metastases.^{42,43} While locoregional or resectable NET-G3 disease may be treated with resection along with regional lymphadenectomy, NET-G3 tumors with PMs are most commonly offered systemic therapy potentially combined with liver-directed locoregional therapies as the initial step.^{42,44} If the disease does not progress on systemic therapy and near complete cytoreductive surgery is predicted, CRS may be offered in select patients.⁴⁵ In cases with progression, further systemic and adjunctive therapies should be prioritized, and CRS may be considered in select cases in conjunction with multidisciplinary consultations.

NECs are an aggressive subset of NENs and are primarily treated with cytotoxic chemotherapy such as platinum/etoposide.^{46,47} Surgical intervention may be offered in limited instances based on disease stage, primary tumor site, the patient's overall health

status, clinical symptoms, and response to systemic therapy after multidisciplinary discussion.

Block 4: Carcinoid syndrome in lower-grade (G1/G2) GEP-NETs with PMs

Agreement: Round 1 - 90%; Round 2 - 96%

Patients with surgically treatable low-grade GEP-NETs should be evaluated for the carcinoid syndrome, which may occur in up to 30% of patients with liver metastases, predominantly from small bowel primary tumors.^{48,49} Carcinoid heart disease can occur in up to half of patients with carcinoid syndrome and is often characterized by plaque-like fibrous buildup on endocardial surfaces or valvular leaflets.⁵⁰ Evaluation for carcinoid heart disease should be performed in all patients with carcinoid syndrome or evidence of serotonin production as manifested by elevated 5-HIAA in blood or urine. Other functional neuroendocrine abdominal malignancies (e.g., Zollinger-Ellison syndrome, insulinoma syndrome, etc) tend to occur in association with pancreatic primary tumors and tend not to be associated with fibrotic complications such that their PM management is similar to that of patients with non-functional NENs.

In grade 1 and 2 NETs, distinctions are made for symptomatic patients, focusing on the differentiation between carcinoid syndrome and other (functional or non-functional) tumors. When present, symptoms from carcinoid syndrome should be addressed initially, and patients started on an SSA.⁵¹ All at-risk patients should be monitored for cardiac disease. If either carcinoid syndrome is present or there is evidence of serotonin overproduction, patients should undergo a transthoracic echocardiogram for further evaluation.⁵² Short-acting octreotide to prevent carcinoid syndrome prior to cytoreductive surgery may be considered but its efficacy remains controversial.⁵³⁻⁵⁵

Symptomatic advanced carcinoid heart disease is most effectively treated with valvular surgery.⁵⁰ In the setting of carcinoid heart disease, CRS, including hepatic resection, is delayed until after valve replacement occurs due to the potential congestive hepatopathy in the setting of right-sided heart failure.⁵¹

Block 4: Cytoreductive surgery in G1/G2 NET-PMs

In the treatment of low-grade well-differentiated NETs, we recommend that cytoreductive surgery be considered, targeting a 70% threshold in the reduction of tumor burden.^{4,56,57} This can be coupled with, or independent of, somatostatin analogues (SSAs). A significant observation is that most tumor bulk is usually hepatic rather than peritoneal. Hence, an open question remains on how the distribution of disease (hepatic vs. peritoneal metastases) might influence resection, current evidence for which remains equivocal. In 2020, *Benhaim et al.* evaluated 88 patients with metastatic NET, who underwent resection of PM, liver metastases, or both, and noted comparable disease-free survival (DFS) in the PM only group when compared to the liver only or the combined group.¹⁷ Those with small bowel primaries demonstrated longer DFS and overall survival (OS) than other primary origins.¹⁷ Another study retrospectively compared hepatic and peritoneal metastases in patients with small intestinal NETs and revealed that PM, either alone or in combination with hepatic metastasis, was associated with a worse prognosis compared to hepatic metastasis alone.²² Therefore, this preliminary work suggests PM resection may have a positive prognostic effect; however, high-level evidence on debulking remains limited, and further studies are needed.

When evaluating surgical interventions, simultaneous resection of the primary tumor and metastases is preferred if near complete CRS is feasible and primary disease is resectable. This strategy often involves addressing hepatic metastases through adjunct methods like parenchymal-sparing hepatectomy or ablation. A retrospective study showed that in patients with small bowel NETs, complete CRS was associated with improved survival compared to partial or no CRS.⁴ Moreover, patients with minimal residual disease showed better survival outcomes than those with more extensive residual disease.⁴ Particularly notable was the finding that patients with minimal peritoneal disease and significant cytoreduction of liver metastases (> 70%) had the longest survival, signifying the importance of cytoreduction in improving survival outcomes for eligible patients.⁴ In patients with unresectable distant metastases, the role of resection of asymptomatic primary tumor is controversial, but few studies have shown improved overall and progression free survival with this strategy.⁵⁸⁻⁶⁰

Currently, hyperthermic intraperitoneal chemotherapy (HIPEC) is generally not used in the treatment of NEN-PMs as it has limited evidence available and has been

associated with a higher toxicity profile.^{19,21} A single-institution series by Elias et al compared the use of CRS with and without HIPEC in 41 patients with NEN-PMs.¹⁹ Overall survival of both treatment groups were similar, although the HIPEC group had an improved DFS rate. However, the authors attributed this difference to increased extra-abdominal metastases in the non-HIPEC group.¹⁹ Another similar study on 67 patients diagnosed with small bowel NETs who underwent CRS with or without HIPEC showed that the CRS-HIPEC group experienced a higher rate of grade III-IV adverse events (>50%) compared to only 3.4% in the CRS alone group.²¹ Furthermore, there were no added benefits in 5-year OS between the CRS-HIPEC and CRS alone groups (91.6% vs 74.5%), nor was there a difference in DFS between the two groups.²¹

In accordance with National Comprehensive Cancer Network (NCCN), North American Neuroendocrine Tumor Society (NANETS), and European Neuroendocrine Tumor Society (ENETS) guidelines, resection of the primary tumor for metastatic NETs should strongly be considered at the time of CRS to avoid locoregional complications, halt ongoing metastatic shedding, and potentially improve survival.^{32,61,62}

Block 5: Bowel obstruction in the setting of carcinomatosis or mesenteric fibrosis

Agreement: Round 1 - 93%; Round 2 - 97%

Bowel obstruction is a frequent complication in patients with NEN-PM, occurring in 3-28% of cases, as highlighted in studies by Merola et al and Strosberg et al.^{5,23,63} It is often associated with mesenteric fibrosis and necessitates surgical intervention when feasible. In instances where near-complete cytoreduction is not possible, palliative surgery or comprehensive supportive care may be considered based on individual performance status, disease biology, metastatic disease burden, and symptom profile (i.e. abdominal pain, recurrent bowel obstruction, malnutrition). These nuances are detailed in our guideline for malignant gastrointestinal obstruction in patients with peritoneal carcinomatosis.⁶⁴ Palliative surgical correction for acute obstruction may yield lasting improvements in survival and quality of life, as demonstrated by De Boer and colleagues. In their institutional review of 135 patients with acute obstruction, 30 patients with NENs experienced longer overall survival (median 562 days, IQR 133-1788) and spent a higher proportion of their remaining life in the hospital (6.9%, IQR 1.3-21.9) compared to patients

with other primary tumors.¹⁸ Additionally, palliative resection of the primary tumor is recommended in the setting of small intestinal NETs with a high likelihood of anticipated bowel obstructions and bleeding, potentially associated with a survival benefit.⁶⁵

Block 6: Asymptomatic low-grade NETs

Agreement: Round 1 - 94%; Round 2 - 95%

In asymptomatic patients with limited disease, surgical resection of the primary tumor, regional lymph nodes, and distant metastases is usually recommended after multidisciplinary discussion. This approach may be combined with systemic therapies, either to manage low volume disease or to prevent complications such as obstruction, bleeding, or perforation in candidates suitable for surgery.^{66,67} The choice between systemic therapy and surgical intervention depends largely on the extent of disease burden and primary site. Since SSTR positivity is ubiquitous, initiating treatment with somatostatin analogues is often considered at diagnosis (particularly if progression has been documented), but in some cases, a purely observational approach can be adopted for those presenting with low-moderate volume asymptomatic disease.

Block 7: Clinical progression of disease

Agreement: Round 1 - 84%; Round 2 - 97%

In cases of clinically significant progression or recurrence, asymptomatic patients with grade 1/2 NETs or those with well-differentiated grade 3 NETs are usually treated with systemic therapy.³² This may be combined with liver-directed treatment for hepatic-dominant disease. The choice of treatment modality varies depending on the characteristics of the primary tumor and is detailed in the section below, “Principles of Systemic Therapy”. For patients who demonstrate further progression despite systemic therapy, CRS may be considered in very select patients considered amenable to complete or near complete cytoreduction, characterized as a CC0-1 resection of peritoneal metastases and successful removal of over 70% of hepatic metastases.

Surveillance for NENs typically consist of a routine history and physical examination followed by appropriate imaging studies (cross-sectional CT or MRI abdominopelvic scans with PET-CTs as clinically indicated). The recommended

surveillance frequency varies by institution but typically involves follow-up every three months for NENs with unfavorable/concerning disease and every six to twelve months for resectable, locoregional disease with favorable characteristics.⁶⁸⁻⁷⁰

Principles of Systemic Therapy

The following recommendations pertain primarily to well-differentiated midgut NETs (distal small intestine and proximal colon), which account for most PMs.⁵

Somatostatin Analogs

Somatostatin analogs (SSAs) are typically the first-line systemic treatment for metastatic well-differentiated NETs due to their proven inhibitory effect on tumor growth and favorable safety profile.⁷¹ SSAs are also effective at palliating carcinoid syndrome. Nearly all midgut NETs express somatostatin receptors which are the target for SSAs.⁷² The phase III PROMID trial compared octreotide long-acting release (LAR) to placebo in 85 patients with well-differentiated metastatic midgut NETs. Median time to progression (TTP) was 14.3 months in the group randomized to receive octreotide-LAR versus 6 months in the placebo group.⁷³ Similarly, the CLARINET study reported a significant improvement in progression-free survival (PFS) in patients with advanced, well-differentiated grade 1 and grade 2 GEP NETs (Ki-67<10%) treated with lanreotide (median PFS not reached at time of data analysis) compared with placebo (median PFS 18 months).⁷⁴ Peritoneal metastases were not directly addressed in either study. SSAs have not been compared to placebo in tumors with KI-67 >10%. Objective response rates with SSAs are generally negligible.

Everolimus

The RADIANT 2 study investigated everolimus plus octreotide versus placebo plus octreotide in patients with metastatic NETs and history of carcinoid syndrome (primarily midgut primaries).⁷⁵ While there was a trend towards improvement in progression free survival (PFS), this did not meet statistical significance. The RADIANT 4 study evaluated everolimus versus placebo in patients with GI and lung NETs lacking carcinoid syndrome, a more aggressive population than studied in RADIANT 2.⁷⁶ This study met its endpoint of

significant PFS improvement (11.0 months vs. 3.9 months, $p < 0.001$). Objective response rate in this study was only 2%.⁷⁶

Despite the lack of statistically significant PFS benefit of everolimus in the RADIANT 2 study, guidelines generally endorse use of everolimus with progressive GI and lung NET, even among patients with history of carcinoid syndrome.⁷⁷ However, the benefits and risks need to be carefully evaluated: adverse effects include oral stomatitis, pneumonitis, diarrhea, immunosuppression and hyperglycemia. There is no data focusing on the role of everolimus among patients with PM.

Sunitinib

Sunitinib was evaluated in 171 patients with advanced, well-differentiated pancreatic NETs, and it was found that the median PFS was 11.4 months in the sunitinib group and 5.5 months in the placebo group.⁷⁸ In this study, 95% of patients had liver metastases and the objective response rate was 9.3% in the sunitinib group, but no data were provided on study drug efficacy according to liver or peritoneal tumor burden. Given the lack of evidence, sunitinib is not considered as a treatment option for patients with PM. Additionally, the use of VEGF inhibitors, such as sunitinib, carry an increased risk of perforation and bleeding.⁷⁹

Peptide Receptor Radionucleotide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE

The NETTER-1 trial studied the benefit of ¹⁷⁷Lu-Dotatate in patients with progressive, well-differentiated, metastatic midgut NETs. The study included 229 patients, 116 in the ¹⁷⁷Lu-Dotatate group (¹⁷⁷Lu-Dotatate plus 30 mg intramuscular octreotide LAR) and 113 in the control group (60 mg intramuscular octreotide LAR). The median PFS was not reached in the ¹⁷⁷Lu-Dotatate group and was 8.4 months in the octreotide LAR group at the time of primary data analysis. The objective response rate was 18% in the ¹⁷⁷Lu-Dotatate group and 3% in the control group. It should be noted that most patients had metastases to the liver or lymph nodes. However, 7% of the patients had PM (7 in the treatment group and 10 in the control group).⁸⁰ The NETTER-2 trial compared ¹⁷⁷Lu-Dotatate with high-dose long acting octreotide (60 mg monthly) as first-line systemic therapy in patients with higher-risk grade 2 NETs (Ki-67 $\geq 10\%$) and well-differentiated

grade 3 NETs (Ki-67 >20% to ≤55%). Upfront PRRT yielded superior progression-free survival (the primary endpoint) to high-dose octreotide, 22.8 months vs. 8.5 months.⁸¹ Seventeen percent of the patients in the PRRT arm had peritoneal metastases but outcomes specific to that group were not reported specifically. Small bowel obstruction occurred in 5 of 147 patients (3.4%) receiving PRRT but none of the 73 patients on high-dose octreotide.

Recent data indicate that extensive peritoneal disease may be a partial contraindication to ¹⁷⁷Lu-Dotatate. One retrospective study showed that PRRT did not control the peritoneal metastases in more than a third of the treated patients, and bowel obstruction was noted following PRRT.⁵ Another study described occurrences of bowel obstruction shortly after PRRT treatment, including two cases of frozen abdomen in patients with high-burden peritoneal carcinomatosis. The bowel obstruction may be caused by transient peritoneal inflammation following PRRT leading to peritoneal and/or mesenteric fibrosis.^{23,63} Corticosteroids have been proposed both for treatment as well as prophylaxis of radiation peritonitis, although their use has not been evaluated in prospective studies.

Additionally, the risk of bowel obstruction related to PRRT in patients with PM strongly correlates with both the number and size of peritoneal disease.^{4,22} Therefore, risks and benefits need to be carefully assessed prior to initiating PRRT, and the timing of surgery relative to PRRT should be addressed in a multidisciplinary setting. Patients with diffuse peritoneal carcinomatosis are likely poor candidates for treatment whereas patients with a small number of tumors are much more likely to tolerate treatment without obstructive complications.

Chemotherapy

Cytotoxic chemotherapy is active in metastatic pancreatic NETs (30-40% response rate), however the role of chemotherapy in midgut NETs is more limited. Chemotherapy regimens such as capecitabine/temozolomide (CAPTEM) are associated with a very low response rate in grade 1 and 2 midgut NETs; however, one retrospective study indicated that response rate may be higher in grade 3 midgut NETs.⁸² FOLFOX and CAPEOX can also be considered in patients with high volume of disease or aggressive clinical progression.

Systemic therapy for NECs

Cisplatin or carboplatin with etoposide remains the standard first-line regimen for metastatic poorly differentiated NEC but other regimens such as FOLFIRINOX may also be reasonable.⁸³ The FOLFIRINEC trial (NCT04325425) is prospectively comparing cisplatin/etoposide with FOLFIRINOX as first-line therapy is ongoing. Given the highly aggressive nature of NEC, the role of surgery is very limited.

DISCUSSION

Herein we summarize the updated consensus guidelines on the management of NENs with PMs. Our current consensus group expanded to include surgical oncologists, medical oncologists, radiologists, pathologists, and patient advocates. Consensus was achieved in all seven question blocks after two rounds of review. Despite the low level of evidence, substantial work had been produced in the field of NENs to require major adoptions and revisions.

The current approach improves upon the classification of NENs with PMs based on disease grading and symptomatology. Key recommendations from the consensus, which received strong support, include the early identification of carcinoid syndrome and its complications, such as carcinoid heart disease, as well as other functional tumors. Those at high risk of carcinoid heart disease should undergo cardiac monitoring. The administration of short-acting octreotide before CRS should be considered in patients with carcinoid syndrome in the setting of NET-PMs to avert carcinoid crisis, although the benefit of this routine practice has recently been called into question. Additionally, in G1 and G2 well-differentiated NETs with PMs, CRS is recommended if the burden of liver and distant metastases is low. This may include parenchymal-sparing hepatectomy or ablative techniques. Moreover, patients experiencing bowel obstruction secondary to PMs, often in the setting of carcinoid fibrosis, may require CRS or palliative surgical correction. Such cases necessitate multidisciplinary supportive care with a focus on symptom mitigation and social support. Lastly, systemic therapy is recommended as first-line treatment in scenarios involving progressive disease of grade 3 NETs or NECs. Recently, the CABINET trial

showed that the use of cabozantinib in advanced extra-pancreatic and pancreatic NETs improved PFS compared to placebo.⁸⁴

Major limitations of this expert consensus merit discussion. Firstly, the available evidence for our rapid review were of low quality and scarce. Therefore, the consensus methodology was employed to provide guidance regarding matters of equipoise. Secondly, the expert panel consisted primarily of surgical oncologists. Having expected this bias from the inception phases, thought leaders in medical oncology and other disciplines were involved early on for reviewing feedback from the first Delphi round and outlining principles of systemic therapy. Lastly, the Delphi consensus entailed voting on blocks rather than individual itemized recommendations, aligning with the original Chicago Consensus framework.^{7,85} While this approach helped mitigate survey fatigue, it may have compromised the granularity of feedback received.

PSOGI: International Perspective

Management of NET-PMs is nuanced and understudied, as evidenced by guidelines from major multi-national organizations, such as European Society for Medical Oncology (ESMO), ENETs, NANETs, and APNETs.^{33,86-89} These conditions are rare, leading to limited specific recommendations. Current guidelines suggest surgery as a primary option for low-grade, low-burden NETs, yet less clarity is provided for NET-PMs. ESMO 2020 recommends surgery for local or locoregional G1 and G2 NETs, advocating for medical management or a watch-and-wait strategy in certain cases, such as those with a low Ki-67 index and stable disease. ENETs 2016 guidelines endorse surgery with curative intent if significant cytoreduction is achievable, aiming to avoid complications such as obstruction, fibrosis-induced events, external bowel compression, or portal hypertension.

Liver metastases, a frequent co-occurrence in NETs, are addressed in several guidelines. ENETs advises cytoreductive surgery for symptom control in functional NETs with liver-dominant disease, even if complete tumor removal is not possible. ESMO 2020 and Nordic 2014 guidelines recommend local treatments and systemic therapies in combination with surgery. Controversy remains regarding the extent of tumor removal necessary for debulking surgery, with recent shifts towards a debulking threshold of 70% from 90%.

In concordance with PSM guidelines, palliative resection of the primary tumor in advanced NETs is typically recommended to avoid complications such as bowel obstruction or ischemia, as per ESMO 2020 guidelines. However, the efficacy of primary tumor removal in improving survival in metastatic disease remains a topic of debate. NEC is highlighted as an absolute contraindication for upfront surgery, with such patients being directed towards systemic therapies or enrollment in clinical trials. Lastly, no clinical data currently exist for perioperative intraperitoneal chemotherapy or HIPEC in the setting of PMs in GEP-NETs.

Patient and Caregiver Perspective

Dealing with NENs that have spread to the peritoneum presents significant challenges for patients and their loved ones. Concerns include the scarcity of clinical trials for advanced NENs and the exclusion of patients with PMs. This exclusion not only limits access to potentially beneficial treatments but also impedes progress in understanding this disease, leaving patients feeling marginalized and without options for advanced care. The difficulty in accurately assessing eligibility for trial enrollment using standard imaging techniques poses another barrier, culminating in uncertainty and anxiety among patients and caregivers about the best course of action.

Inclusion of patients with PM in clinical trials is especially important in addressing complications such as diffuse carcinomatosis, ascites, bile acid diarrhea, and malignant bowel obstruction. These conditions are particularly debilitating and can impact quality of life. Unfortunately, patients with malignant bowel obstruction are often doubly disadvantaged, being excluded from both oral antineoplastic therapies and intravenous (IV) treatments. Centers that are well-equipped with the necessary medical and psychosocial resources to facilitate a comprehensive, multidisciplinary approach are essential for effectively addressing the complexities of PM.

Patients have also emphasized the importance of using outcome measures addressing quality of life, palliation, and functional status alongside traditional metrics such as survival, complication rates, and response to therapy. Akin to the clinical trials guide provided by LACNETs, patients have expressed a need for informational handouts on

managing a life with advanced NENs, including access to resources for mental and emotional health.

CONCLUSION

In summary, we report an updated Delphi consensus on the management of NENs with peritoneal metastasis that included a multidisciplinary team of experts, including surgical/medical oncologists, radiologists, pathologists, and patient support groups. Cytoreductive surgery is highly recommended in cases of well-differentiated, low-grade NETs with treatable peritoneal and hepatic metastases. Higher grade, well differentiated disease typically undergoes systemic therapy considerations prior to consideration of cytoreduction. NECs are usually treated with up-front chemotherapy.

References

1. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. *Endocrine Pathology*. 2022;33(1):115-154.
2. Thiis-Evensen E, Boyar Cetinkaya R. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021. *J Neuroendocrinol*. Apr 2023;35(4):e13264. doi:10.1111/jne.13264
3. White BE, Rous B, Chandrakumaran K, et al. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. *Lancet Reg Health Eur*. Dec 2022;23:100510. doi:10.1016/j.lanepe.2022.100510
4. Wonn SM, Limbach KE, Pommier SJ, et al. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. *Surgery*. Jan 2021;169(1):168-174. doi:10.1016/j.surg.2020.03.030
5. Merola E, Prasad V, Pascher A, et al. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. *Neuroendocrinology*. 2020;110(6):517-524. doi:10.1159/000503144
6. Madani A, Thomassen I, van Gestel Y, et al. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. *Ann Surg Oncol*. Aug 2017;24(8):2199-2205. doi:10.1245/s10434-016-5734-x
7. The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. *Annals of surgical oncology*. 2020;27(6):1788-1792.
8. Alejandro P, Izquierdo FJ, Darryl S, Sherman SK, Kiran T. The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. *Annals of Surgical Oncology*. 2020;27(6):1741-1742.
9. Consensus Guidelines for the Management of Peritoneal Surface Malignancies: Introduction and Methodology. *Submitted*. 2024;
10. Group CCW, Turaga K, Ahuja N, et al. The Chicago consensus guidelines for peritoneal surface malignancies: introduction. *Cancer*. 2020;126(11):2510-2512.
11. Leanne Brown, David Su, Craig Gunderson, Turaga K. The Utility of Cytoreductive Surgery and Medical Management of Neuroendocrine Neoplasms with Peritoneal Dissemination: A Rapid Review. *PROSPERO*. 2023;CRD42023465271(Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023465271)
12. Babineau J. Product review: Covidence (systematic review software). *Journal of the Canadian Health Libraries Association/Journal de l'Association des bibliothèques de la santé du Canada*. 2014;35(2):68-71.
13. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC medical research methodology*. 2008;8(1):1-9.
14. Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World Journal of Meta-Analysis*. 2017;5(4):80-84.

15. Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. *Journal of clinical epidemiology*. 2021;130:13-22.
16. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *International journal of surgery*. 2021;88:105906.
17. Benhaim L, Faron M, Hadoux J, et al. Long-term results after surgical resection of peritoneal metastasis from neuroendocrine tumors. *Neuroendocrinology*. 2021;111(6):599-608.
18. de Boer NL, Hagemans JA, Schultze BT, et al. Acute malignant obstruction in patients with peritoneal carcinomatosis: the role of palliative surgery. *European Journal of Surgical Oncology*. 2019;45(3):389-393.
19. Elias D, David A, Sourrouille I, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). *Surgery*. 2014;155(1):5-12.
20. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. *Surgery*. 2005;137(4):411-416.
21. Hajjar R, Mercier F, Passot G, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. *European Journal of Surgical Oncology*. 2022;48(7):1626-1630.
22. Wright MF, Cates J, Gonzalez RS, Das S, Berlin JD, Shi C. Impact of peritoneal metastasis on survival of patients with small intestinal neuroendocrine tumor. *The American journal of surgical pathology*. 2019;43(4):559-563.
23. Strosberg JR, Al-Toubah T, Pellè E, et al. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. *J Nucl Med*. Jan 2021;62(1):69-72. doi:10.2967/jnumed.120.242875
24. Kimbrough CW, Beal EW, Dillhoff ME, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. *Surgery*. 2019;165(3):657-663.
25. Kaltsas G, Caplin M, Davies P, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre-and perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology*. 2017;105(3):245-254.
26. Hughes MS, Azoury SC, Assadipour Y, et al. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). *Surgery*. 2016;159(1):350-357.
27. Eads JR, Halfdanarson TR, Asmis T, et al. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. *Endocrine-related cancer*. 2023;30(8)
28. Tsimopoulou I, Pasquali S, Howard R, et al. Psychological prehabilitation before cancer surgery: a systematic review. *Annals of surgical oncology*. 2015;22:4117-4123.

29. Yachida S, Totoki Y, Noë M, et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. *Cancer discovery*. 2022;12(3):692-711.
30. Shi M, Fan Z, Xu J, et al. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*. 2021;1876(2):188637.
31. Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. *Cancers*. 2022;14(10):2514.
32. Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*. 2021;19(7):839-868.
33. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2020;31(7):844-860.
34. Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*. Mar 2 2017;543(7643):65-71. doi:10.1038/nature21063
35. Raj N, Shah R, Stadler Z, et al. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. *JCO Precision Oncology*. 2018;(2):1-18. doi:10.1200/po.17.00267
36. Desai H, Borges-Neto S, Wong TZ. Molecular imaging and therapy for neuroendocrine tumors. *Current treatment options in oncology*. 2019;20:1-13.
37. Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. *Neuroendocrinology*. 2017;105(3):212-244.
38. Schwenzer NF, Schmidt H, Gatidis S, et al. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: Comparison with ^{18}F -FDG-PET. *Journal of Magnetic Resonance Imaging*. 2014;40(5):1121-1128.
39. Pellat A, Coriat R. Well differentiated grade 3 neuroendocrine tumors of the digestive tract: a narrative review. *Journal of Clinical Medicine*. 2020;9(6):1677.
40. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Annals of oncology*. 2013;24(1):152-160.
41. Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. *Annals of Surgical Oncology*. 2014;21:2956-2962.
42. Merola E, Rinke A, Partelli S, et al. Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms? *Annals of surgical oncology*. 2020;27:1348-1355.
43. Yoshida T, Hijioka S, Hosoda W, et al. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. *Ann Surg Oncol*. May 2019;26(5):1385-1393. doi:10.1245/s10434-019-07252-8


44. Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). *Cancers*. 2021;13(8):1936.
45. Gangi A, Anaya DA. Surgical principles in the management of small bowel neuroendocrine tumors. *Current treatment options in oncology*. 2020;21:1-13.
46. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. *Cancer*. 2018;124(4):807-815.
47. Mollazadegan K, Welin S, Crona J. Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma. *Current Treatment Options in Oncology*. 2021;22(8):68.
48. Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. *Therapeutic advances in endocrinology and metabolism*. 2019;10:2042018818804698.
49. Kianmanesh R, Ruzsiewicz P, Rindi G, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. *Neuroendocrinology*. 2010;91(4):333-340.
50. Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. *Journal of the American College of Cardiology*. 2017;69(10):1288-1304.
51. Grozinsky-Glasberg S, Davar J, Hofland J, et al. European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. *Journal of Neuroendocrinology*. 2022;34(7)
52. Barnebee D, Morse B, Strosberg JR, Pejic M, Jeong D. Cardiac magnetic resonance for diagnosis of neuroendocrine tumor metastases to the right and left ventricles with carcinoid heart disease. *Case Reports in Cardiology*. 2019;2019
53. Leiting JL, Grotz TE. Neuroendocrine Peritoneal Metastases. *Neuroendocrine Tumors: Surgical Evaluation and Management*. 2021:283-291.
54. Wonn SM, Ratzlaff AN, Pommier SJ, McCully BH, Pommier RF. A prospective study of carcinoid crisis with no perioperative octreotide. *Surgery*. 2022;171(1):88-93.
55. Bardasi C, Benatti S, Luppi G, et al. Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency. *Cancers (Basel)*. Jan 28 2022;14(3)doi:10.3390/cancers14030662
56. Gudmundsdottir H, Habermann EB, Vierkant RA, et al. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients. *Ann Surg Oncol*. Aug 2023;30(8):4840-4851. doi:10.1245/s10434-023-13372-z
57. Woltering EA, Voros BA, Beyer DT, et al. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution. *J Am Coll Surg*. Apr 2017;224(4):434-447. doi:10.1016/j.jamcollsurg.2016.12.032
58. Dijke K, Kuhlmann KFD, Levy S, Tesselaar MET. Surgical Management of the Primary Tumor in Stage IV Small Intestinal Neuroendocrine Tumors: To Operate or Not to Operate, That Is the Question. *Curr Oncol Rep*. Jun 2023;25(6):679-688. doi:10.1007/s11912-023-01405-5

59. Stålberg P. Metastatic small-bowel neuroendocrine tumours: medical management of the primary. *Br J Surg*. Aug 1 2023;doi:10.1093/bjs/znad248
60. Lewis A, Raof M, Ituarte PHG, et al. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. *Ann Surg*. Dec 2019;270(6):1131-1137. doi:10.1097/SLA.0000000000002809
61. Hallet J, Law C, Meyer-Rochow CNTRCSSJHCLJPJKW. Role of primary tumor resection for metastatic small bowel neuroendocrine tumors. *World Journal of Surgery*. 2021;45:213-218.
62. Gangi A, Manguso N, Gong J, et al. Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection. *Annals of surgical oncology*. 2020;27:4525-4532.
63. Wee CE, Dundar A, Eiring RA, et al. Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. *J Nucl Med*. Sep 1 2021;62(9):1320. doi:10.2967/jnumed.121.262048
64. Varun V. Bansal, Elizabeth Godfrey, David G. Su, et al. Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies. *Annals of surgical oncology*. 2024;Submitted.
65. Niederle B, Pape U-F, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. *Neuroendocrinology*. 2016;103(2):125-138.
66. Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. *World J Gastrointest Endosc*. May 16 2022;14(5):267-290. doi:10.4253/wjge.v14.i5.267
67. De Mestier L, Lardière-Deguelte S, Brix H, et al. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. *Neuroendocrinology*. 2015;101(2):105-111.
68. Halfdanarson TR, Strosberg JR, Tang L, et al. The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. *Pancreas*. 2020;49(7):863-881.
69. Tran CG, Sherman SK, Scott AT, et al. It is time to rethink biomarkers for surveillance of small bowel neuroendocrine tumors. *Annals of surgical oncology*. 2021;28:732-741.
70. Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. *Surgical Oncology Clinics*. 2020;29(2):223-241.
71. Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. *International journal of molecular sciences*. 2020;21(5):1682.
72. Watanabe H, Fujishima F, Komoto I, et al. Somatostatin receptor 2 expression profiles and their correlation with the efficacy of somatostatin analogues in gastrointestinal neuroendocrine tumors. *Cancers*. 2022;14(3):775.
73. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*. 2009;27(28):4656-4663.

74. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *New England Journal of Medicine*. 2014;371(3):224-233.
75. Pavel M, Baudin E, Öberg K, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. *Annals of Oncology*. 2017;28(7):1569-1575.
76. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *The Lancet*. 2016;387(10022):968-977.
77. Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline. *Journal of clinical oncology*. 2023;41(32):5049-5067.
78. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *New England Journal of Medicine*. 2011;364(6):501-513.
79. Qi W-X, Sun Y-J, Tang L-N, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. *Critical reviews in oncology/hematology*. 2014;89(3):394-403.
80. Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020;47:2372-2382.
81. Singh S, Halperin DM, Myrehaug S, et al. [177Lu] Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. American Society of Clinical Oncology; 2024.
82. Al-Toubah T, Morse B, Strosberg J. Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. *Curr Oncol*. Jan 26 2022;29(2):510-515. doi:10.3390/currenol29020046
83. Eads JR, Halfdanarson TR, Asmis T, et al. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. *Endocr Relat Cancer*. Aug 1 2023;30(8)doi:10.1530/erc-22-0206
84. Chan J, Geyer S, Ou F, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). *Annals of Oncology*. 2023;34:S1292.
85. Group; CCW, Turaga K. The Chicago consensus on peritoneal surface malignancies: methodology. *Annals of Surgical Oncology*. 2020;27(6):1741-1742.
86. Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS). *Pancreas*. 2017;46(6):715.

87. Kianmanesh R, Ruzniewski P, Rindi G, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. *Neuroendocrinology*. 2010;91(4):333-340.
88. Janson ET, Sorbye H, Welin S, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. *Acta Oncologica*. 2014;53(10):1284-1297.
89. Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. *Neuroendocrinology*. 2016;103(2):172-185.

Peritoneal Metastasis from Neuroendocrine Neoplasms



Assessing for:

- Distribution of hepatic disease
- Nodal involvement
- synchronous vs. metachronous
- Mesenteric retraction
- Vascular involvement
- Primary tumor, if present
- Grade and differentiation

GEP-NET: Gastroenteropancreatic Neuroendocrine Tumor
 CT C/A/P: Computed Tomography of Chest/Abdomen/Pelvis
 SSR PET/CT: Somatostatin Receptor Positron Emission Tomography/Computed Tomography
 5-HIAA: 5-Hydroxyindolacetic acid
 MRI: Magnetic Resonance Imaging
 CRS: Cytoreductive Surgery
 NET: Neuroendocrine tumors
 NEC: Neuroendocrine carcinoma
 SSA: somatostatin analog
 PRRT: Peptide receptor radionuclide therapy

¹Patient support groups, social work, genetic counseling, fertility counseling, nutritionists, psychosocial as indicated.

²Considerations of systemic therapy and/or surgical intervention are predicated on disease burden and location of primary. If SSTR+, start SSAs.

³Liberal use of diagnostic laparoscopy to assess feasibility of complete/near-complete CRS is strongly encouraged. Near-complete CRS is defined as CC0-1 or 70% or greater reduction of tumor burden

⁴Consider resection of primary, regional nodes, and metastases with systemic therapy for low volume disease or to reduce future obstruction, bleeding, or perforation in surgically fit candidates. Observation is only considered in very low burden disease.

⁵Selection considerations: Low Ki-67 and mitoses, low burden of disease, non-functional tumor, patient functional and health status.

Surveillance:

- H&P, PE
- CT, MRI, +/- DOTATATE PET/CT
- 5-HIAA (if carcinoid syndrome)

*every 3-6 months to annually, depending on tumor grade, sites of metastases, and response to treatment.
 *Plan should be individualized




Figure 2: PRISMA Flow Diagram for Study Selection for Rapid Review

Table 1. Delphi Round 1 agreement table

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agreement
Block 1	66	37	1	2	1	107	96%
Block 2	65	33	6	1	2	107	92%
Block 3	55	40	7	4	1	107	89%
Block 4	64	35	5	0	3	107	93%
Block 5	56	45	4	0	2	107	94%
Block 6	58	42	4	1	2	107	93%
Block 7	51	41	8	3	4	107	86%

Table 2. Delphi Round 2 agreement table

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agreement
Block 1	76	11	1	0	0	88	99%
Block 2	78	8	1	0	1	88	98%
Block 3	73	11	3	0	1	88	95%
Block 4	73	13	2	0	0	88	98%

Block 5	75	11	1	1	0	88	98%
Block 6	75	10	2	0	1	88	97%
Block 7	74	13	1	0	0	88	99%

Table 3. Description of Studies from Rapid Review

Author	Year Published	Country	Study Aim	Study design	Start Date	End Date	Study Population	Number of patients	Outcomes
Benhaim et al. [17]	2020	France	To evaluate if surgical resection could lead to prolonged survival for patients with peritoneal metastases	Single-institution, retrospective	1995	2017	Patients with well-differentiated NETs	88 (PM=12, LM=41, LM+PM=35)	No difference in 5-year OS rate between groups [81% (60–100) PM vs. 78% (65.2– 92.8) LM vs. 72% (58.7–89.7) PM + LM (p = 0.71)]; No difference in 3-year DFS rate between groups [12.5% (2.3–68.2) PM, vs. 26.9% (16.1–45.1) LM vs. 32.4% (19.9–52.6) PM + LM (p = 0.45)]; Patients with SB origin had improved OS/DFS than pancreas
Boer et al. [18]	2018	Netherlands	To evaluate outcomes of palliative surgery for acute MBO	Single-institution, retrospective	2005	2017	Patients with acute obstruction caused by peritoneal carcinomatosis who underwent palliative surgery	30 with NETs (148 overall)	NETs - improved OS (median 562 days, iQR 133-1788) and greater remaining life spent outside of hospital after discharge compared to other tumor types.
Elias et al. [19]	2014	France	To report the results of complete CRS of peritoneal metastases from NET and compare patients treated with or without HIPEC	Single-institution, retrospective	1994	2012	Patients who underwent macroscopically complete resection of well-differentiated NETs with slow tumor growth under systemic treatment (at least a 20% increase in tumor burden in the preceding 12 months)	41 (28 CRS-HIPEC, 13 CRS alone)	5- & 10-year OS 69% & 52%, respectively - no difference between CRS-HIPEC and CRS alone groups; 5- & 10-year DFS 17% and 6%, respectively - improved in HIPEC group in univariable analysis (fewer lung and bone metastases); no difference in major morbidity between groups
Elias et al. [20]	2005	France	To assess the prognostic impact of palliative surgery in NET-PMs	Single-institution, retrospective	1993	2003	Well-differentiated endocrine carcinoma patients (WHO 2000 Classification); two groups according to extent of resection: 1) complete resection of macroscopic peritoneal disease not possible (patients only underwent palliative debulking), 2) maximal CRS with immediate HIPEC	37 (20 palliative surgery, 17 complete CRS)	5-year OS 66.2% complete CRS-HIPEC vs 40.9% palliative surgery; grade 3-4 morbidity higher in CRS-HIPEC group; CRS-HIPEC group - 41% patients were disease-free right after surgery and 10% disease-free 5 years postop
Hajjar et al. [21]	2022	International Cohort	To evaluate the addition of HIPEC to CRS	Multicenter retrospective	2002	2016	Patients with small bowel-NET with PMs who underwent CRS or CRS-HIPEC	67 (36 CRS-HIPEC, 31 CRS alone)	No difference in 5-year OS between CRS-HIPEC and CRS-alone (74.5% vs. 91.6%, p = 0.32). No difference in DFS in CRS-HIPEC and CRS-alone groups (30.8% vs. 0%, p = 0.78). CRS-HIPEC group had higher G3/G4 adverse events compared to CRS alone (>50% vs 3.4%, p < 0.001).
Merola et al. [5]	2019	Germany	To describe the clinical impact of PM and to report the effectiveness of available treatments in PM control	Single-institution, retrospective	1993	2016	Patients with sporadic GEP-NENs with PMs and a minimum of 12-month follow up after PM detection.	135 (43 peritonectomy, 90 SSAs, 32 PRRT, 50 chemotherapy, 18 everolimus, 1 sunitinib)	First line therapy of SSAs demonstrated improved PFS survival (median: 114 months) compared to PRRT (25 months), everolimus (35 months), chemotherapy (13 months). Peritonectomy was associated with best PFS (152 months) compared to any other first line intervention (p<0.01). Overall no difference in RFS between complete, partial, or in combination with HIPEC peritonectomies (p=0.45). 22.2% of patients developed bowel obstruction at a median of 16 months after the diagnosis of PM.
Wonn et al. [4]	2020	United States	To determine how much cytoreduction needed for small bowel NETs with PMs and LMs can be achieved and corresponding survival benefits of different levels of clearance	Single-institution, retrospective	2008	2019	Patients with histologically confirmed NETs	98 (complete CRS 49, incomplete CRS 49)	Improved OS with complete vs. incomplete CRS (OS 135 vs 51 mo, p = 0.03); Within incomplete CRS group, pts with localized nodules < 5 mm had improved OS vs. > 5mm size nodules (76 vs 32 mo, p = 0.04); patients who underwent cytoreduction for MPD and LM had longer survival (76.5 mo) compared to other groups: patients with extensive residual PM+LM cytoreduced at least 70% (39 mo), MPD+LM not cytoreduced (22 mo), extensive peritoneal disease and LM not cytoreduced (20 mo)

Wright et al. [22]	2019	United States	To clarify prognostic significance of peritoneal metastasis in midgut NET patients	Single-institution, retrospective	1991	2017	Patients with midgut NET with PMs who underwent surgical resection	219 overall (80 LM; 14 PM, 53 PM + LM, 70 no mets)	Median OS 156 mo LM only vs. 133 mo PM only vs. 82 mo PM + LM (p < 0.01). Patients with PM had T4 primary lesions more frequently than those with LM only or no distant metastases.
Strosberg et al. [23]	2021	United States	To investigate the incidence of PRRT-induced bowel obstruction	Single-institution, retrospective	2018	2019	Patients with NET & mesenteric or peritoneal disease who received ¹⁷⁷ Lu-DOTATATE	159 overall (81 PM/mesenteric disease)	3% of all patients, 22% of high risk patients (extensive peritoneal or desmoplastic changes associated with mesenteric tumors) developed bowel obstruction within three months of PRRT. All patients with documented obstruction demonstrated symptomatic improvement after initiation of corticosteroid treatment.

CRS: cytoreductive surgery; NET: neuroendocrine tumor; PM: peritoneal metastasis; LM: liver metastasis; PRRT: peptide receptor radionuclide therapy; SSA: somatostatin analogue; HIPEC: hyperthermic intraperitoneal chemotherapy; GEP-NEN: gastroenteropancreatic-neuroendocrine neoplasms; MPD: minimal peritoneal disease; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; DSS: disease-specific survival

Table 4. Systemic therapies in neuroendocrine neoplasms with peritoneal metastases

WHO Grade	Patient Presentation	Initial Therapy/Intervention	Subsequent Therapy/Intervention	Special Considerations
Well Differentiated Grade 1-2 NET	Asymptomatic or Slow Disease Progression	Somatostatin analogues (SSAs) if SSTR-positive Observation*	SSTR-positive and progression on SSAs: PRRT with 177Lu-dotatate** Everolimus	Cytotoxic chemotherapy (if no other options feasible or ongoing progressive disease): *** CAPTEM# FOLFOX CAPEOX Cabozantinib## Double dose SSA in select cases Telotristat if carcinoid syndrome diarrhea###
	Carcinoid Syndrome Symptoms	Somatostatin analogues (SSAs) if SSTR-positive	Sunitinib (Pancreas only) <u>Consider CRS and primary tumor resection if predicted near or complete CRS</u>	
	Obstructive Symptoms	<u>Consider operative intervention</u>	Limited evidence for the use of adjuvant therapy in NETs****	
Well Differentiated Grade 3 NET	Asymptomatic/Symptomatic	Consider somatostatin analogues (SSAs) (depends on SSTR status, Ki67, site of primary, etc.) Everolimus Sunitinib (Pancreas only) Chemotherapy: Capecitabine/temozolomide FOLFOX	SSTR-positive and progression on SSAs: PRRT with 177Lu-dotatate** <u>Consider surgical resection in select patients after systemic therapy</u>	CAPTEM# FOLFOX CAPEOX FOLFIRI Carboplatin/etoposide Cabozantinib## Double dose SSA in select cases
Poorly Differentiated NEC	Asymptomatic/Symptomatic	Chemotherapy Carboplatin/cisplatin + etoposide Carboplatin/cisplatin + irinotecan FOLFOX FOLFIRINOX Temozolomide ± capecitabine	<u>Surgical resection is not recommended</u>	Dual checkpoint inhibitors (CPI) may be considered in select cases of microsatellite stability and high TMB.####

Table adapted from NCCN Guidelines

Patients should undergo multidisciplinary evaluation prior to initiation of systemic therapy.
Consider additional octreotide dosing schedule for added symptomatic control.

* Observation with short interval follow up is an option in asymptomatic low volume disease, especially if grade 1 or at the lower end of the grade 2 spectrum.

** PRRT can be used in combination with SSAs if functional tumor is present. Note that PRRT carries a risk of bowel obstruction and steroids can be considered for prophylaxis and treatment of obstructive symptoms after PRRT.

*** Individualized regimens should be discussed in multidisciplinary review

**** SSAs are often continued if there is residual disease after surgery.

In pancreatic NETs, CapTem may be considered as initial treatment in symptomatic cases or cases with large tumor burden.

Not FDA-approved

Rule out bile acid malabsorption as a cause of diarrhea in patients with NENs.

Single agent CPI may be considered in MSI-H or TMB-H well-differentiated G3 NET or NEC